Download PDF
Pharmacopsychiatry 2001; 34(1): 19-24
DOI: 10.1055/s-2001-15191
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Influence of Treatment of Tourette Syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC) on Neuropsychological Performance

K. R. Müller-Vahl1 , A. Koblenz1 , M. Jöbges2 , H. Kolbe2 , H. M. Emrich1 , U. Schneider1
  • 1Department of Clinical Psychiatry and Psychotherapy
  • 2Department of Neurology
  • Medical School Hannover, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Previous studies have suggested that marijuana (cannabis sativa) and delta-9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient of marijuana, are effective in the therapy of tics and associated behavioral disorders in Tourette Syndrome (TS). Because there is also evidence that cannabis sativa may cause cognitive impairment in healthy users, we performed a randomized double-blind placebo-controlled crossover trial for Δ9-THC in 12 adult TS patients to investigate whether treatment of TS with a single dose of Δ9-THC at 5.0 to 10.0 mg causes significant side effects on neuropsychological performance. Using a variety of neuropsychological tests, we found no significant differences after treatment with Δ9-THC compared to placebo treatment in verbal and visual memory, reaction time, intelligence, sustained attention, divided attention, vigilance, or mood. Only when using the Symptom Checklist 90-R (SCL-90-R) did our data provide evidence for a deterioration of obsessive-compulsive behavior (OCB) and a trend towards an increase in phobic anxiety. However, these results should be interpreted with caution as SCL-90-R has known limitations on measuring OCB. We suggest that the increase in phobic anxiety is mainly due to the fact that a single-dose treatment rules out the possibility of administering the dosage slowly. In contrast to results obtained from healthy marijuana users, a single-dose treatment with Δ9-THC in patients suffering from TS does not cause cognitive impairment. We therefore suggest that further investigations should concentrate on the effects of a longer-term therapy of TS with Δ9-THC.

References

  • 1 Arnold W. Der Pauli-Test. Berlin; Springer 1975
    Google Scholar
  • 2 Benton A L. A visual retention test for clinical use.  Arch Neurol Psychol. 1945;  59 273-291
    PubMedGoogle Scholar
  • 3 Block R I, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques.  Pharmacol Biochem Behav. 1992;  43 907-917
    CrossrefPubMedGoogle Scholar
  • 4 Block R I, Ghoneim M M. Effects of chronic marijuana use on human cognition.  Psychopharmacology (Berl.). 1993;  110 219-228
    PubMedGoogle Scholar
  • 5 Brito G N O. A neurobiological model for Tourette syndrome centered on the nucleus accumbens.  Med Hypothesis. 1997;  49 133-142
    CrossrefPubMedGoogle Scholar
  • 6 Chan P K, Chan S C, Yung W H. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurons by cannabinoid agonist.  Neuroreport. 1998;  9 671-675
    PubMedGoogle Scholar
  • 7 Clifford D B. Tetrahydrocannabinol for tremor in multiple sclerosis.  Ann Neurol. 1983;  13 669-671
    CrossrefPubMedGoogle Scholar
  • 8 Comings D E, Comings B G. Comorbid behavioral disorders. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc. 1993: 111-147
    Google Scholar
  • 9 Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis.  Eur Neurol. 1997;  38 44-48
    PubMedGoogle Scholar
  • 10 Consroe P, Sandyk R, Snider S R. Open label evaluation of cannabidiol in dystonic movement disorders.  Int J Neurosci. 1986;  30 277-282
    PubMedGoogle Scholar
  • 11 Crawley J N, Corwin R L, Robinson J K, Felder C C, Devane W A, Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents.  Pharmacol Biochem Behav. 1993;  46 967-972
    CrossrefPubMedGoogle Scholar
  • 12 Derogatis L R, Lipman R S, Covi L. SCL-90: an outpatient psychiatric rating scale - preliminary report.  Psychopharmacol Bull. 1973;  9 13-28
    PubMedGoogle Scholar
  • 13 Derogatis L R. SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine 1977
    Google Scholar
  • 14 Devane W A, Hanus L, Breuer A, Pertwee R G, Stevenson L A, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.  Science. 1992;  258 1946-1949
    CrossrefPubMedGoogle Scholar
  • 15 Emrich H M, Leweke F M, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.  Pharmacol Biochem Behav. 1997;  56 803-807
    CrossrefPubMedGoogle Scholar
  • 16 Gessa G L, Melis M, Muntoni A L, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.  Eur J Pharmacol. 1998;  341 39-44
    Google Scholar
  • 17 Golden G S. Psychologic and neuropsychologic aspects of Tourette Syndrome.  Neurologic Clin. 1984;  2 91-102
    PubMedGoogle Scholar
  • 18 Gorriti M A, Rodriguez de Fonseca F, Navarro M, Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.  Eur J Pharmacol. 1999;  365 133-142
    CrossrefPubMedGoogle Scholar
  • 19 Grotenhermen F, Karus M. Marihuana: Die rechtliche Situation in Deutschland. Der Stand der medizinischen Forschung. In Marihuana, die verbotene Medizin. Zweitausendeins, Frankfurt am Main 1994 1. Aufl: 211-272
    Google Scholar
  • 20 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 56-62
    CrossrefPubMedGoogle Scholar
  • 21 Hamilton M. Development of rating scale for primary depressive illness.  Br J Soc Clin Psychol. 1967;  6 278-296
    PubMedGoogle Scholar
  • 22 Hampson R E, Deadwyler S A. Role of cannabinoid receptors in memory storage.  Neurobiol Dis. 1998;  5 474-482
    CrossrefPubMedGoogle Scholar
  • 23 Helmstadter C, Durwen H F. VLMT. Verbaler Lern- und Merkfähigkeitstest.  Schweiz Arch Neurol Psychiatr. 1990;  141 21-30
    PubMedGoogle Scholar
  • 24 Hemming M, Yellowlees P M. Effective treatment of Tourette Syndrome with marijuana.  J Psychopharmacol. 1993;  7 389-391
    CrossrefPubMedGoogle Scholar
  • 25 Herkenham M, Lynn A B, Little M D, Johnson M R, Melvin L S, de Costa B R, Rice K C. Cannabinoid receptor localization in brain.  Proc Natl Acad Sci USA. 1990;  87 1932-1936
    CrossrefPubMedGoogle Scholar
  • 26 Hill M, Armitage P. The two period cross-over clinical trial.  Br J Clin Pharmacol. 1979;  8 7-20
    PubMedGoogle Scholar
  • 27 Hollister L E. Health aspects of cannabis.  Pharmacol Rev. 1986;  38 1-20
    PubMedGoogle Scholar
  • 28 Jentsch J D, Andrusiak E, Tran A, Bowers M B, Roth R H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966.  Neuropsychopharmacology. 1997;  16 426-432
    CrossrefPubMedGoogle Scholar
  • 29 Johannes S, Weber A, Müller-Vahl K R, Kolbe H, Dengler R, Münte T F. Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette syndrome.  Eur J Neurology. 1997;  4 152-161
    PubMedGoogle Scholar
  • 30 Kim S W, Dysken M W, Kuskowski M. The Symptom Checklist-90: Obsessive-Compulsive Subscale: A reliability and validity study.  Psychiatry Res. 1992;  41 37-44
    CrossrefPubMedGoogle Scholar
  • 31 Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor.  Biol Pharm Bull. 1998;  21 224-226
    PubMedGoogle Scholar
  • 32 Kleiber D, Kovar K-A. Psychische und soziale Konsequenzen des Cannabiskonsums. In: Kleiber D, Kovar K-A (ed.) Auswirkungen des Cannabiskonsums: eine Expertise zu pharmakologischen und psychosozialen Konsequenzen. Stuttgart; Wissenschaftliche Verlagsgesellschaft mbH 1998: 88-225
    Google Scholar
  • 33 Korzyn A D. Future therapies. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc 1993: 199-220
    Google Scholar
  • 34 Leckman J F, Towbin K E, Ort S I, Cohen D J. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF Tourette Syndrome and tic disorders. New York; John Wiley 1988: 55-78
    Google Scholar
  • 35 Mailleux P, Vanderhaeghen J-J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons.  Neurosci Lett. 1992;  148 173-176
    CrossrefPubMedGoogle Scholar
  • 36 Maneuf Y P, Nash J E, Crossman A R, Brotchie J M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.  Eur J Pharmacol. 1996;  308 161-164
    CrossrefPubMedGoogle Scholar
  • 37 Marsden C D. Treatment of torsion dystonia. Barbeau, A. (ed.) Disorders of Movement. Current status of modern therapy. Philadelphia; Lippincott 1981 8: 81-104
    Google Scholar
  • 38 Merz J, Lehrl S, Galster J V, Erzigkeit H. MWT-B - ein Intelligenzkurztest.  Psychiatr Neurol Med Psychol. 1975;  27 423-428
    PubMedGoogle Scholar
  • 39 Miller A S, Sanudo-Pena M C, Walker J M. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus.  Brain Res. 1998;  793 7-11
    CrossrefPubMedGoogle Scholar
  • 40 Miller A S, Walker J M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata.  Eur J Pharmacol. 1995;  279 179-185
    CrossrefPubMedGoogle Scholar
  • 41 Molina-Holgado F, Amaro A, Gonzalez M I, Alvarez F J, Leret M L. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system.  Eur J Pharmacol. 1996;  316 39-42
    CrossrefPubMedGoogle Scholar
  • 42 Müller-Vahl K R, Kolbe H, Schneider U, Emrich H M. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome.  Acta Psychiat Scand. 1998;  98 502-506
    PubMedGoogle Scholar
  • 43 Müller-Vahl K R, Schneider U, Koblenz A, Jöbges M, Kolbe H, Dahltrup T, Emrich H M. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol (THC): a randomized crossover trial. (submitted)
    Google Scholar
  • 44 Müller-Vahl K R, Schneider U, Kolbe H, Emrich H M. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol.  Am J Psychiatry. 1999;  156 495
    PubMedGoogle Scholar
  • 45 Palumbo D, Maughan A, Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome.  Arch Neurol. 1997;  54 475-483
    PubMedGoogle Scholar
  • 46 Pope H G, Gruber A J, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research.  Drug Alcohol Depend. 1995;  38 25-34
    PubMedGoogle Scholar
  • 47 Pope H G, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students.  JAMA. 1996;  275 521-527
    CrossrefPubMedGoogle Scholar
  • 48 Sandyk R, Awerbuch G. Marijuana and Tourette Syndrome.  J Clin Psychopharmacol. 1988;  8 444-445
    CrossrefPubMedGoogle Scholar
  • 49 Sandyk R, Snider S R, Consroe P, Elias S M. Cannabidiol in dystonic movement disorders.  Psychiatry Res. 1986;  18 291
    CrossrefPubMedGoogle Scholar
  • 50 Sanudo-Pena M C, Walker J M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat.  J Neurophysiol. 1997;  77 1635-1638
    PubMedGoogle Scholar
  • 51 Schneider U, Leweke F M, Müller-Vahl K R, Emrich H M. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?.  Pharmacopsychiatry. 1998;  31 (Suppl. 2) 110-113
    PubMedGoogle Scholar
  • 52 Schwartz R H, Gruenewald P J, Klitzner M, Fedio P. Short-term memory impairment in cannabis-dependent adolescents.  Am J Dis Child. 1989;  143 1214-1219
    PubMedGoogle Scholar
  • 53 Shapiro A K, Shapiro E, Young J G, Feinberg T E. Gilles de la Tourette Syndrome. Raven Press, New York 2d ed 1988
    Google Scholar
  • 54 Shen M, Piser T M, Seybold V S, Thayer S A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.  J Neurosci. 1996;  16 4322-4334
    PubMedGoogle Scholar
  • 55 Shen M, Thayer S A. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.  Mol Pharmacol. 1999;  55 8-13
    PubMedGoogle Scholar
  • 56 Sieradzan K A, Fox S H, Dick J, Brotchie J M. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD).  Mov Disord. 1998;  13 (Suppl. 2) 29
    CrossrefPubMedGoogle Scholar
  • 57 Solowij N, Michie P T, Fox A M. Differential impairments of selective attention due to frequency and duration of cannabis use.  Biol Psychiatry. 1995;  37 731-739
    CrossrefPubMedGoogle Scholar
  • 58 Swets J A, Green D M, Getty D J, Swets J B. Signal detection and identification at successive stages of observation.  Percept Psychopsy. 1978;  23 275-289
    PubMedGoogle Scholar
  • 59 Varma V K, Malhotra A K, Dang R, Das K, Nehra R. Cannabis and cognitive functions: a prospective study.  Drug Alcohol Depend. 1988;  21 147-152
    PubMedGoogle Scholar
  • 60 Wechsler D. A standardized memory scale for clinical use.  J Psychol. 1945;  19 87-95
    PubMedGoogle Scholar
  • 61 Wechsler D. Die Messung der Intelligenz Erwachsener. Bern; Huber Verlag 1956
    Google Scholar
  • 62 Weeks R A, Turjanski N, Brooks D J. Tourette Syndrome: a disorder of cingulate and orbitofrontal function?.  QJM. 1996;  89 401-408
    PubMedGoogle Scholar
  • 63 Woody S R, Steketee G, Chambless D L. The usefulness of the Obsessive Compulsive Scale of the Symptom Checklist-90-Revised.  Behav Res Ther. 1995;  33 607-611
    PubMedGoogle Scholar
  • 64 Yordanova J, Dumais-Huber C, Rothenberger A, Woerner W. Frontocortical activity in children with comorbidity of tic disorder and attention-deficit hyperactivity disorder.  Biol Psychiatry. 1997;  41 585-594
    CrossrefPubMedGoogle Scholar
  • 65 Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation.  Am J Psychiatry. 1997;  154 1277-1284
    PubMedGoogle Scholar
  • 66 Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg 1989
    Google Scholar

Dr. med. Kirsten R. Müller-Vahl

Department of Clinical Psychiatry and Psychotherapy
Medical School Hannover

Carl-Neuberg-Straße 1

30625 Hannover

Germany

Phone: +49-511-5323110

Fax: +49-511-5323115

Email: Mueller-Vahl.Kirsten@MH-Hannover.de